Immutep advances its LAG-3 agonist for autoimmune diseases
Filed with ASX · · 2 pages · English
Earlier from Immutep
- Immutep presents TACTI-002 data at AACR Virtual Meeting
- EOC Pharma confirms plans to advance Efti in China for MBC
- Immutep AIPAC Ph2b Clinical Results & Update Webcast Slides
- Immutep reports supportive efficacy data from AIPAC study
- Immutep receives 2nd IND approval for efti from US FDA
Later from Immutep
- Immutep March Quarterly Activities Report & Appendix 4C
- Enrollment completed for the INSIGHT-004 Study
- Immutep Reports Positive Phase II TACTI-002 Data
- Immutep Investor Presentation
- INSIGHT-004 and TACTI-002 data to be presented at ASCO
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep